tradingkey.logo
tradingkey.logo

Integra Lifesciences Holdings Corp

IART
12.660USD
+0.070+0.56%
終値 12/24, 13:00ET15分遅れの株価
985.39M時価総額
損失額直近12ヶ月PER

Integra Lifesciences Holdings Corp

12.660
+0.070+0.56%

詳細情報 Integra Lifesciences Holdings Corp 企業名

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.

Integra Lifesciences Holdings Corpの企業情報

企業コードIART
会社名Integra Lifesciences Holdings Corp
上場日Aug 16, 1995
最高経営責任者「CEO」Poul (Mojdeh)
従業員数4396
証券種類Ordinary Share
決算期末Aug 16
本社所在地1100 Campus Road
都市PRINCETON
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号08540
電話番号16092750500
ウェブサイトhttps://www.integralife.com/
企業コードIART
上場日Aug 16, 1995
最高経営責任者「CEO」Poul (Mojdeh)

Integra Lifesciences Holdings Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.59M
-11.20%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%
Mr. Harvinder Singh
Mr. Harvinder Singh
Executive Vice President, President - International Business
Executive Vice President, President - International Business
21.94K
+65.53%
Ms. Mojdeh Poul
Ms. Mojdeh Poul
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Shaundra D. Clay
Ms. Shaundra D. Clay
Independent Director
Independent Director
--
--
Mr. Chris Ward
Mr. Chris Ward
IR Contact Officer
IR Contact Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.59M
-11.20%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Neurosurgery
208.99M
50.29%
Wound Reconstruction and Care
84.75M
20.39%
Private Label
26.90M
6.47%
地域別USD
会社名
収益
比率
United States
306.31M
73.70%
Asia Pacific
47.73M
11.48%
Europe
42.59M
10.25%
Rest of World
18.97M
4.56%
事業別
地域別
事業別USD
会社名
収益
比率
Neurosurgery
208.99M
50.29%
Wound Reconstruction and Care
84.75M
20.39%
Private Label
26.90M
6.47%

株主

更新時刻: Sat, Nov 15
更新時刻: Sat, Nov 15
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.36%
Fuller & Thaler Asset Management Inc.
5.03%
他の
52.94%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.36%
Fuller & Thaler Asset Management Inc.
5.03%
他の
52.94%
種類
株主統計
比率
Investment Advisor/Hedge Fund
36.53%
Investment Advisor
36.42%
Hedge Fund
18.48%
Corporation
10.93%
Individual Investor
3.20%
Research Firm
2.31%
Pension Fund
1.49%
Bank and Trust
0.44%
Sovereign Wealth Fund
0.04%

機関投資家保有株

更新時刻: Sun, Oct 5
更新時刻: Sun, Oct 5
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
583
73.55M
94.42%
-25.07M
2025Q2
600
89.38M
114.72%
-18.72M
2025Q1
635
87.01M
111.97%
-18.30M
2024Q4
636
81.93M
106.10%
-20.27M
2024Q3
638
82.93M
106.93%
-12.58M
2024Q2
628
84.82M
107.92%
-1.75M
2024Q1
613
79.36M
101.18%
-3.69M
2023Q4
597
79.81M
101.26%
-5.74M
2023Q3
592
81.88M
100.31%
-3.94M
2023Q2
587
82.30M
100.29%
-6.57M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
9.43M
12.11%
-322.52K
-3.31%
Jun 30, 2025
TRU ST Partnership, L.P.
8.52M
10.93%
--
--
Feb 28, 2025
Rubric Capital Management LP
7.35M
9.44%
+2.71M
+58.36%
Jun 30, 2025
The Vanguard Group, Inc.
7.50M
9.63%
+34.14K
+0.46%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
3.89M
5%
-29.99K
-0.76%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.92M
3.74%
+333.71K
+12.91%
Jun 30, 2025
Invesco Advisers, Inc.
3.18M
4.08%
+51.84K
+1.66%
Jun 30, 2025
State Street Investment Management (US)
2.83M
3.63%
+79.03K
+2.88%
Jun 30, 2025
Boston Management and Research
2.74M
3.52%
--
--
Jun 30, 2025
Paradigm Capital Management, Inc.
2.18M
2.8%
+796.30K
+57.49%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Neuroscience and Healthcare ETF
1.44%
State Street SPDR S&P Health Care Equipment ETF
1.39%
ROBO Global Healthcare Technology & Innovation ETF
1.02%
Invesco S&P SmallCap Health Care ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.43%
Inspire Small/Mid Cap ESG ETF
0.19%
Royce Quant Small-Cap Quality Value ETF
0.13%
Principal U.S. Small-Cap ETF
0.13%
iShares S&P Small-Cap 600 Value ETF
0.12%
State Street SPDR S&P 600 Small Cap Value ETF
0.11%
詳細を見る
iShares Neuroscience and Healthcare ETF
比率1.44%
State Street SPDR S&P Health Care Equipment ETF
比率1.39%
ROBO Global Healthcare Technology & Innovation ETF
比率1.02%
Invesco S&P SmallCap Health Care ETF
比率0.49%
Invesco NASDAQ Future Gen 200 ETF
比率0.43%
Inspire Small/Mid Cap ESG ETF
比率0.19%
Royce Quant Small-Cap Quality Value ETF
比率0.13%
Principal U.S. Small-Cap ETF
比率0.13%
iShares S&P Small-Cap 600 Value ETF
比率0.12%
State Street SPDR S&P 600 Small Cap Value ETF
比率0.11%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Integra Lifesciences Holdings Corpの上位5名の株主は誰ですか?

Integra Lifesciences Holdings Corpの上位5名の株主は以下のとおりです。
BlackRock Institutional Trust Company, N.A.は9.43M株を保有しており、これは全体の12.11%に相当します。
TRU ST Partnership, L.P.は8.52M株を保有しており、これは全体の10.93%に相当します。
Rubric Capital Management LPは7.35M株を保有しており、これは全体の9.44%に相当します。
The Vanguard Group, Inc.は7.50M株を保有しており、これは全体の9.63%に相当します。
Fuller & Thaler Asset Management Inc.は3.89M株を保有しており、これは全体の5.00%に相当します。

Integra Lifesciences Holdings Corpの株主タイプ上位3種は何ですか?

Integra Lifesciences Holdings Corpの株主タイプ上位3種は、
BlackRock Institutional Trust Company, N.A.
TRU ST Partnership, L.P.
Rubric Capital Management LP

Integra Lifesciences Holdings Corp(IART)の株式を保有している機関の数はいくつですか?

2025Q3時点で、Integra Lifesciences Holdings Corpの株式を保有している機関は583社あり、保有株式の総市場価値は約73.55Mで、全体の94.42%を占めています。2025Q2と比較して、機関の持ち株は-20.30%増加しています。

Integra Lifesciences Holdings Corpの最大の収益源は何ですか?

FY2025Q2において、Neurosurgery部門がIntegra Lifesciences Holdings Corpにとって最大の収益を生み出しており、その金額は208.99Mで、全収益の50.29%を占めています。
KeyAI